Become Affiliate

PepFlow

Download

The GH Fragment

AOD-9604

A synthetic analog of a human-growth-hormone C-terminal fragment, discussed for fat-metabolism biology rather than full growth-hormone replacement.

Weight loss
TierE
EvidenceLimited
SafetyLimited Data
FDA statusNot Approved
Last reviewed October 25, 2026 18 citations How to read these labels

What is AOD-9604?

AOD-9604 is a modified fragment of the C-terminal region of human growth hormone. It is discussed as a lipolytic or fat-metabolism peptide, not as full growth hormone replacement.[5][6]

Direct mechanistic support is mainly preclinical, including rodent studies of fat oxidation, lipolysis, and weight gain. Public human weight-loss support is much thinner than modern GLP-1 or incretin-drug evidence.[7][8][10]

The naming can be confusing: AOD-9604 is grouped with growth-hormone fragments, while the direct obesity literature is much smaller than approved obesity-drug evidence.[9][10] For more context, read the AOD-9604 preparation terminology guide.

What AOD-9604 is investigated for

AOD-9604 evidence is grouped by practical use case and injectable and intra-articular route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Fat breakdown and metabolism

Mixed research context

32%Limited

The biology is plausible but not enough to support human weight-loss expectations.[7][10]

Human evidence

Published human efficacy support is weak and does not establish a reliable weight-loss effect.[10]

Animal / mechanistic evidence

Rodent and tissue studies support biological activity around lipolysis, beta-adrenergic signaling, and fat oxidation.[7][8][5]

Cartilage repair and osteoarthritis

Injectable

30%Limited

Cartilage repair has preclinical support for AOD-9604, but human osteoarthritis relief has not been established.[17]

Human evidence

No human osteoarthritis data establish AOD-9604 as a joint-repair treatment.[17]

Animal / mechanistic evidence

A rabbit collagenase-induced knee osteoarthritis model reported cartilage-regeneration signals after intra-articular AOD-9604, with stronger findings when combined with hyaluronic acid.[17]

Weight loss and fat loss

Mixed research context

18%Insufficient

AOD-9604 is not a proven weight-loss or fat-loss peptide.[10][9]

Human evidence

Older clinical-development discussion does not establish reliable weight-loss or fat-loss improvement in humans.[10][9]

Animal / mechanistic evidence

Preclinical fat-metabolism findings explain the interest in fat loss, but they do not translate into a confident human result.[7][8]

Evidence snapshot

24%

Human evidence

Insufficient

Public human weight-loss support is historically thin and does not establish a reliable obesity-treatment effect.[10][9]

44%

Animal / preclinical

Limited

Rodent and tissue studies support biological activity around lipolysis, fat oxidation, and weight-gain models, but those findings do not establish human outcomes.[7][8][5]

42%

Mechanism support

Limited

The mechanism rationale centers on a growth-hormone fragment domain and lipid-metabolism effects, with no modern clinical evidence package comparable to approved obesity drugs.[5][6][10]

Forms & administration

AOD-9604 has oral, intravenous and experimental injectable formulations. Animal-only delivery approaches and current research-market injections differ in preparation and exposure. Their amounts cannot be transferred between formulations; human preparation and administration requirements remain incompletely established.[1][9][2][17]

InjectableIntra-articular

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Common injectable protocols use 250-500 mcg per dose. Oral protocols use about 1 mg per day.[9][10][2]

Frequency

Injectable protocols usually use 1-2 doses daily. Oral protocols are usually once daily.[9][10]

Timing Considerations

Common timing is morning or before a workout.[9][10]

Cycle Length

Injectable cycles commonly run 8-12 weeks. Oral protocols run about 24 weeks.[9][10]

What to expect

Early weeks

Early changes are more likely to look like ordinary weight fluctuation than a clear peptide-specific fat-loss effect.[10]

8-12 weeks

A clear waist or scale change is unlikely without matching nutrition and training changes, and human evidence does not support GLP-1-like weight-loss expectations.[10]

Longer term

Large or reliable fat-loss effects remain unlikely on AOD-9604 alone; any visible change is more likely to be modest and hard to separate from the rest of the routine.[10][2]

After stopping

Weight and waist are likely to keep following nutrition, training, and baseline metabolic factors after the protocol ends, because AOD-9604 has not shown a durable reset effect in humans.[10][2]

Safety profile

AOD-9604 safety handling is dominated by product and regulatory concerns: no approved product identified, FDA compounding safety risks, limited clinical usefulness, and explicit sports prohibition.[1][2]

Cautions

  • Immunogenicity risk[2]
  • Impurities and characterization[2]
  • Athlete prohibited
  • Pregnancy and special populations[1][2]

What we don't know

Human long-term safety, dose-response, product purity, and route-specific risk remain unresolved.[2]

Who AOD-9604 is not for

Route-specific avoid and medical-review notes:

  • Competitive athletes

    AOD-9604 is explicitly prohibited under WADA growth hormone fragment language.

  • Pregnancy and special populations

    No approved label or robust human safety package supports use in pregnancy, breastfeeding, pediatric use, frailty, or complex endocrine disease.[1][2]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

  • Growth-hormone-axis products

    Stacking AOD-9604 with growth hormone, GH secretagogues, or other weight-loss/metabolic drugs could compound or confuse appetite, weight, lipid, and adverse-effect signals; no human evidence establishes a safe or effective combination protocol.[10][2]

Pairing notes

Not recommended with

GH, GHRH, GHRP, or metabolic fat-loss stacksMixed research context, Injectable

AOD-9604 has no validated human combination regimen with GH, GHRH, GHRP, or other weight-loss agents. Its injectable use has limited safety data, potential immunogenicity and impurity concerns, and serious adverse-event reports with unclear causality. Adding other agents introduces unstudied combination exposure, and AOD-9604 is prohibited in tested sport.[18][2]

Related peptides

How it works

AOD-9604 is a growth-hormone fragment built around lipid-metabolism interest, not full GH replacement. The strongest signal is preclinical fat oxidation and lipolysis biology, which keeps the page in a low-confidence bucket.[5][7][8]

That mechanism does not establish human fat loss. Older oral, injected, and experimental contexts are not interchangeable, and the obesity-development story did not become an approved therapy. Human usefulness remains the weak link.[10][9][1]

FDA compounding concerns and WADA growth-hormone-fragment language make the mechanism a caution point, not reassurance for self-use, stacking, tested athletes, or a clinical protocol.[2]

Research gaps & open questions

What the current literature has not yet settled about AOD-9604:

01

Peer-reviewed, placebo-controlled trials still need to show whether AOD-9604 produces meaningful, lasting weight loss in people and which dose and route were used.[10]

02

Each route needs direct studies of how the body handles AOD-9604, whether immune reactions occur, and what happens with long-term exposure; product purity also needs reliable testing.[2]

03

For athletes, the practical unanswered question is how product contamination and use affect testing risk; the anti-doping rule is clearer than the weight-loss evidence.

Common questions

Is AOD-9604 the same as growth hormone?

No. It is a synthetic fragment analog related to the C-terminal region of human growth hormone, not full growth hormone replacement.[5]

Does AOD-9604 work for weight loss?

Published evidence does not support strong human weight-loss confidence. Most direct support is preclinical, with weak public clinical usefulness compared with approved obesity drugs.[7][10]

Is AOD-9604 banned in sport?

Yes. WADA explicitly names growth hormone fragments including AOD-9604 in the prohibited list.

Myths & misconceptions

Myth

Because AOD-9604 is only a fragment, it is automatically safe.

Reality

A smaller fragment does not eliminate product-quality, immune, regulatory, or anti-doping risks. FDA specifically flags compounded AOD-9604 safety concerns.[2]

Myth

Rodent fat-loss studies prove human fat loss.

Reality

Rodent lipolysis and fat-oxidation findings are biological plausibility, not proof of meaningful human weight loss.[7][10]

Myth

If it is not a steroid, it is not banned.

Reality

WADA prohibits many peptide hormones, growth factors, related substances, and fragments; AOD-9604 is explicitly named.

History & discovery

AOD-9604 moved from growth-hormone-fragment lipid-metabolism research into obesity-drug interest, then into anti-doping and compounding controversy. Its reputation grew wider than the human outcome evidence, so the useful history is cautionary.[5][9][10][2]

Early rodent and lipid-metabolism papers framed AOD-9604 as a synthetic growth-hormone fragment, and later development summaries described it as a metabolic obesity-drug candidate, but approval did not follow.[5][7][9][10]

WADA and FDA materials shifted the practical history toward sports eligibility, product quality, and compounding risk rather than treating the early GH-fragment mechanism as clinical validation.[4][2]

Published research18 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Stay on track with your weight-management goals.

Use PepFlow to record your AOD-9604 protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00